Business Wire

Keyaki Capital Launches Japan's First Online Private Asset Investment Platform

15.4.2025 16:11:00 CEST | Business Wire | Press Release

Share

Keyaki Capital, a Tokyo-based, VC-backed, and tech-enabled financial services platform led by CEO Taiki Kimura, announced today the official launch of its Online Private Asset Investment Platform.

This platform is the first of its kind in Japan to exclusively offer private equity, private credit, and other private asset investment funds online to high-net-worth investors, following Keyaki Capital's registration to conduct electronic offering services for privately placed funds under Japan’s Financial Instruments and Exchange Act (according to internal research as of April 2025).

Globally, digital investment platforms providing individual investors with seamless access to institutional-quality private asset funds have rapidly expanded across North America, Europe, and Asia. Keyaki Capital is now pioneering this global trend in Japan, enabling domestic investors to benefit from greater transparency and easier access to previously unavailable private investment opportunities.

At launch, the platform features an open-ended Private Credit Fund currently distributed by Keyaki Capital, alongside the newly introduced Marina Investment Fund — a distinctive investment opportunity uniquely aligned with the firm’s corporate vision. Keyaki Capital also plans to introduce additional private capital funds, including private equity, private credit, real estate, and venture capital funds.

Since its establishment, Keyaki Capital has consistently pursued a broader mission to enhance transparency, investor protection, and ease of access to private market investments through digital innovation. Today’s launch marks an important step toward fulfilling that vision.

About Keyaki Capital

Founded in 2020, Keyaki Capital is a Tokyo-based, VC-backed, and tech-enabled financial services platform whose mission is to provide Japanese high-net-worth investors with greater access and transparency in alternative investment markets. Leveraging its proprietary, state-of-the-art digital investor portal, Keyaki Capital offers comprehensive services, including detailed investment offerings and portfolio tracking. The platform primarily targets investments in private equity, private credit, venture capital, and real estate assets, aiming to deliver an enriching and exhilarating investment experience for individual investors.

Staying true to this guiding philosophy, Keyaki Capital continues to diversify its offerings beyond traditional private equity and private credit. Last year, the firm successfully offered investors access to a unique fund investing in music copyrights associated with globally renowned artists. Moving forward, Keyaki Capital remains committed to introducing similarly distinctive and compelling investment opportunities that align with this vision.

For more information, please visit: https://keyakicapital.jp (Japanese language only)

View source version on businesswire.com: https://www.businesswire.com/news/home/20250415702577/en/

Contacts

Keyaki Capital
Email: info@keyakicapital.co.jp
Website: https://keyakicapital.jp -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fkeyakicapital.
jp&esheet=54238330&newsitemid=20250415702577&lan=en-US&anchor=https%3A%2F%2Fkeya
kicapital.jp&index=2&md5=30e009120fc9c897e520a31665bab10b

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye